Financial Performance - Record quarter-end AUM of $829 billion, with 17% in Private Wealth and 83% in Asset Management[5] - 2Q25 adjusted base management fees were up +6% y/y & down -2% q/q, compared to channel avg AUM levels up +8% y/y & down -1% q/q[18] - The firm's blended base fee rate was 38.7 bps in 2Q25, down -2% q/q & y/y, reflecting mix shift[7] - Adjusted operating margin was 32.3% in 2Q25, compared to 30.8% in 2Q24 and 33.7% in 1Q25[10,31] - AB Holding adjusted diluted net income per unit was $0.76 in 2Q25, compared to $0.71 in 2Q24 and $0.80 in 1Q25[10,31] Flows and AUM Composition - Active outflows of $4.8 billion in 2Q25, skewed in April, with demand rebounding in June and pipeline building[5] - Retail posted its first outflowing quarter as overseas demand steps back from turbulent macro[18] - Institutional channel saw positive active net flows in 2Q, >$300 million, driven by taxable FI and alts; outflows concentrated in equities, ~60% passive[25] - Private alts fundraising ~$0.6 billion in 2Q, broad-based across franchises[30] - Equitable ("EQH") AUM reached $137.8 billion in 2Q25, compared to $127.1 billion in 2Q24 and $132.1 billion in 1Q25[10] - Private Markets AUM* reached $77.1 billion in 2Q25, compared to $64.1 billion in 2Q24 and $75.3 billion in 1Q25[10] Strategic Initiatives and Outlook - The company is targeting $90-$100 billion AUM in Private Markets by 2027[9] - The company expects total FY25 performance fees of $110–$130 million, up from $90–105 million across private and public strategies[39,41] - The company is on track for 33% FY25 margins assuming flat markets[42]

Financial Data and Key Metrics Changes - In Q2 2025, total company operational sales grew 22% and organic sales grew 17%, exceeding the guidance range of 13% to 15% [6][23] - Adjusted EPS for Q2 was $0.75, representing a 23% increase, also surpassing the guidance range of $0.71 to $0.73 [6][23] - Adjusted operating margin was 27.6%, an increase of 50 basis points compared to Q2 2024 [7][24] Business Line Data and Key Metrics Changes - Urology sales grew 28% operationally and 6% organically, driven by stone management and prosthetic urology franchises [11] - Endoscopy grew 8% globally, with double-digit growth in the U.S., supported by strong performance in key products [12] - Cardiology sales increased by 28%, with interventional cardiology therapy sales growing 9% [13] Market Data and Key Metrics Changes - U.S. operational growth was 31%, primarily driven by the cardiovascular portfolio [8][9] - EMEA grew 2% operationally, with 7% growth excluding the Accurate Valve discontinuation [9] - Asia Pacific saw a 15% operational growth, led by strong performance in Japan, China, and Australia [10] Company Strategy and Development Direction - The company is focusing on expanding its portfolio and investing in clinical evidence to support new technologies [15][21] - There is a commitment to strategic acquisitions and high-growth adjacencies, with recent acquisitions of Sonae V and Entera Medical [26] - The company aims to continue outpacing market growth through organic portfolio enhancements and strategic M&A [94] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory, expecting full-year organic growth to be in the range of 14% to 15% [28][29] - The anticipated impact of tariffs and the Accurate Valve discontinuation was discussed, with expectations for gross margin to remain flat for the year [24][45] - Management highlighted the importance of clinical data and reimbursement developments in driving future growth [72][75] Other Important Information - The company received a credit rating upgrade from Moody's to A3, reflecting improved financial stability [26] - Free cash flow for Q2 was $1,129 million, with expectations for full-year free cash flow to be approximately $3,500 million [26] Q&A Session Summary Question: WATCHMAN growth and durability - Management noted strong growth in WATCHMAN, driven by safety and efficacy, with expectations for continued growth in the future [35][38] Question: Gross margin concerns - Management addressed the impact of the Accurate Valve discontinuation on gross margin, emphasizing strong sales performance and cost controls [42][44] Question: Growth vectors for EP business - Management highlighted market growth, PFA adoption, and new product introductions as key growth drivers for the electrophysiology business [49][50] Question: MedSurg business performance - Management emphasized strong performance in Endoscopy and Neuromodulation, with expectations for continued growth despite some competitive pressures [55][60] Question: ASC setting and growth implications - Management expressed optimism about the ASC setting, viewing it as a positive development for future growth despite potential challenges [64][68] Question: Renal denervation market potential - Management discussed the potential of the renal denervation market, emphasizing the importance of clinical trials and market positioning [71][75] Question: Evolution of the EP portfolio - Management outlined plans for expanding the EP portfolio, including new product launches and indication expansions [78][82]

Financial Data and Key Metrics Changes - For Q2 2025, the company achieved 8% adjusted and organic revenue growth and 16% adjusted EPS growth, with an adjusted operating margin of 39.6%, an increase of 120 basis points year-over-year [5][33] - Free cash flow for the quarter was $1,200,000,000, with expectations of approximately $5,500,000,000 for the full year [34][35] - The company refined its full-year organic revenue growth guidance to approximately 10%, at the low end of the previous range of 10% to 12% [7][46] Business Line Data and Key Metrics Changes - In the Merchant Solutions segment, organic revenue growth was 9% for both the quarter and year-to-date, with Clover revenue growing 30% in Q2 [35][39] - The Financial Solutions segment saw organic revenue growth of 7% in the quarter, driven by strong growth in issuing and digital payments [40][42] - Clover's volume growth was reported at 8%, with an adjusted growth of 11% excluding the gateway conversion [10][36] Market Data and Key Metrics Changes - The company reported a significant increase in Clover's value-added services (VAS) revenue, which grew 52% [11] - The international expansion of Clover is progressing well, particularly in Brazil, Mexico, and Canada, with new partnerships enhancing market penetration [12][13] Company Strategy and Development Direction - The company is focused on expanding its Clover platform through new products, markets, and partnerships, aiming to enhance its distribution channels and drive growth [9][20] - Strategic initiatives include the launch of Clover Hospitality and partnerships with TD Bank and Adobe to enhance service offerings [14][21] - The company is also investing in its digital payment solutions and cash flow management tools to meet evolving customer needs [30][31] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in capturing strategic and financial benefits from new product launches, despite some delays in execution [6][7] - The macroeconomic environment has been uncertain, impacting the timing of product rollouts and client implementations [78][79] - The company anticipates an acceleration in organic revenue growth in the second half of the year, particularly in the Merchant Solutions segment [46] Other Important Information - The company returned $2,200,000,000 to shareholders through share repurchases in the quarter, increasing its share repurchase guidance to approximately 130% of free cash flow [5][44] - Total debt outstanding was $29,600,000,000, with a debt to adjusted EBITDA ratio steady at 2.9 times [43][44] Q&A Session Summary Question: Insights on Clover Capital penetration - Management acknowledged that Clover Capital is underpenetrated compared to peers and discussed ongoing efforts to unlock total addressable market (TAM) through operational refinements and risk management strategies [49][52] Question: Changes in merchant growth rate expectations - Management clarified that the refinement in growth expectations is due to a combination of slower product rollouts and macroeconomic factors, not a decline in product quality [58][60] Question: Details on merchant operating margins - Management explained that the decline in merchant margins was anticipated due to acquisitions and investments in marketing and product development, which are expected to yield long-term benefits [85][88] Question: Acceleration in growth rates for the second half - Management indicated that the expected acceleration in growth rates is supported by easier year-over-year comparisons and continued expansion of Clover and Commerce Hub [91][94]

Financial Performance Highlights - Moody's achieved its second-highest Q2 revenue on record[9] - Moody's Analytics (MA) Annualized Recurring Revenue (ARR) reached $33 billion, an increase of 8% year-over-year[9] - Adjusted Operating Margin increased by 130 basis points to 509%[12] - Adjusted Diluted EPS increased by 9% to $356[12] Moody's Investors Service (MIS) Performance - MIS revenue outpaced issuance by approximately 12%[13] - MIS achieved an Adjusted Operating Margin of 642%, up 100 basis points[12, 16] - Total MIS rated issuance guidance was updated to reflect a decrease in the low-single-digit to mid-single-digit percent range[27, 36] Moody's Analytics (MA) Performance - MA experienced strong recurring revenue growth, with recurring revenue accounting for 96% of total revenue[19] - MA's Adjusted Operating Margin increased by 360 basis points to 321%[12, 19] - Decision Solutions led with 10% ARR growth[12] - MA revenue grew by 11% year-over-year[19] Updated Full Year 2025 Guidance - MCO revenue growth is projected to be in the mid-single-digit percent range[10] - Adjusted Diluted EPS is now expected to be in the range of $1350 to $1400[12] - The company plans to repurchase at least $13 billion in shares[39]